Navigation Links
Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
Date:5/15/2013

with afatinib discontinued treatment compared with 39.8 percent of patients treated with chemotherapy.1  

LUX-Lung 6 (Patient-Reported Outcomes) Abstract: #8061
Poster: Saturday, June 1, 8:00-11:45 AM, poster board #35A

Patient-reported outcomes (PROs) were also evaluated as secondary endpoints of the LUX-Lung 6 trial and included analyses of health-related quality of life (QoL) and lung cancer-related symptoms compared with chemotherapy.[5]

The analysis of lung cancer-related symptoms – cough, dyspnea (shortness of breath) and pain – was conducted using the European Organization for Research and Treatment of Cancer (EORTC) QoL questionnaire for lung cancer (QLQ-LC13).5 Results showed:

  • A higher proportion of patients in the afatinib arm, compared with those in the chemotherapy arm, reported 10 point or more improvements in cough (76% versus 55%; p=0.0003), dyspnea (71% versus 48%; p<0.0001) and pain (64% versus 47%; p=0.003)5
  • Afatinib-treated patients experienced a significant delay in the worsening (time to deterioration) of cough (HR=0.45; p=0.0001), dyspnea (HR=0.54; p<0.0001) and pain (HR=0.70; p=0.03) compared to those treated with chemotherapy5

Health-related QoL was evaluated using the EORTC QLQ-C30 questionnaire, which evaluated global health status/QoL (overall well-being) in addition to physical, cognitive, role, social and emotional functioning.6 Based on these measures, afatinib-treated patients experienced improvements in their global health-related QoL (p<0.0001) and physical (p<0.0001), role (p=0.01) and social (p<0.001) functioning compared to chemotherapy.5

A significantly higher proportion of afatinib-treated patients had worsening of diarrhea, sore mouth and dysphagia; while fatigue, nausea and vomiting were significantly worse with gemcit
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... YORK , Aug. 20, 2014 ... market research report is available in its catalogue: ... Medical Records http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html ... market for electronic medical records (EMR) for nearly ... comprehensive report of our findings. Our report has ...
(Date:8/20/2014)... England , August 20, 2014 ... be Conducted in the US  KalVista Pharmaceuticals ... macular edema (DME), today announces that it has begun ... novel plasma kallikrein inhibitor, KVD001, for the treatment of ... Sun of the Beetham Eye Institute, Joslin Diabetes Center; ...
(Date:8/19/2014)... KIRKLAND, Wash. , Aug. 19, 2014 ... solutions, will be exhibiting at the 2014 NPPA Summer ... The company will be showcasing its 340B software products ... leader in 340B splitting solutions, supplying over 400 customers ... a range of 340B solutions including its latest solution, ...
Breaking Medicine Technology:EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Talyst Exhibits at the NPPA Summer Conference 2
...   Unigene Laboratories, Inc. (OTCBB: UGNE), today announced ... position of Chief Financial Officer. In this newly created position, ... company,s executive leadership team and lead the strategic direction ... Mr. Moskowitz joins Unigene after spending the previous ...
... 2012 Reportlinker.com announces that a new ... catalogue: Vaccines - ... This market research report package offers ... situation, trends and future outlook for vaccines ...
Cached Medicine Technology:Unigene Appoints David Moskowitz as Chief Financial Officer 2Unigene Appoints David Moskowitz as Chief Financial Officer 3Unigene Appoints David Moskowitz as Chief Financial Officer 4Unigene Appoints David Moskowitz as Chief Financial Officer 5Vaccines - Asia 2
(Date:8/20/2014)... York, New York (PRWEB) August 20, 2014 ... with the use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) ... LLP notes that two U.S. Senators from New York ... to seek a recall of the devices. In a ... Schumer, both Democrats, also implored the agency to seriously ...
(Date:8/20/2014)... contrast to evidence that the amygdala stimulates stress ... Research Center, Emory University have found that the ... during the early development of nonhuman primates. , ... Journal of Neuroscience . , The amygdala is ... important for responses to threatening situations and learning ...
(Date:8/20/2014)... Reinberg HealthDay Reporter TUESDAY, ... that dismantles a baby,s immune system is twice as common ... million infants says. This is the first evaluation of ... condition known as severe combined immunodeficiency (SCID), or "Bubble Boy" ... this condition by the boy in the bubble, who was ...
(Date:8/20/2014)... Santa Rosa, CA (PRWEB) August 20, 2014 ... is the 12 per diode panel band perfect spectrum that ... plants are most likely to use during photosynthesis. A ... spectral bands is that they almost exclusively reside between 440-480 ... 620-680 on the red side of the spectrum. The KIND ...
(Date:8/20/2014)... 2014 Braverman Eye Center is now ... their experienced surgeons trained in PresbyLasik. The Braverman Eye ... lost or inaccurate vision. Their diligent service and adoption ... making it possible for Presbyopia patients to have better ... in people in the age group of 40 to ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2Health News:Braverman Eye Center Now Offers Multifocal PresbyLasik in Florida by Trained Surgeons 2
... for young people do not always provide the same quality ... As our population ages and requires more healthcare, hospitals need ... over 65s and implement programs to meet their distinct needs, ... St. Michael,s Hospital. The study, published in the June ...
... (HealthDay News) -- People who seek treatment in an emergency ... likely to be readmitted to the hospital as those who ... The finding suggests that emergency departments can help reduce the ... were to present the study Friday at the Society for ...
... Reinberg HealthDay Reporter , THURSDAY, June 2 ... Americans to eat healthier meals and fight the obesity ... icon called MyPlate. MyPlate replaces the U.S. Department ... but had become too complicated in ensuing years, many ...
... conserving therapy for women 70 years and older with ... opting for radioactive implants and those with estrogen positive ... an abstract being presented at the American Society of ... University Hospital researchers on Saturday, June 4. The ...
... are one step closer to helping millions of people ... or damage from treatment of diseases. The ... Oral Health and Rehabilitation, UofL School of Dentistry, and ... the salivary gland. The National Institutes of Health supported ...
... 2 (HealthDay News) -- Obesity and insulin resistance constitute a ... according to a new study that found drinking modest amounts ... condition. For their study, published online May 23 in ... people to either abstain from alcohol or drink one (women) ...
Cached Medicine News:Health News:Not all hospitals treat elderly the same 2Health News:Emergency Care May Be Key to Hospital Readmissions 2Health News:U.S. Serves Up New Nutrition Guidelines on 'MyPlate' 2Health News:U.S. Serves Up New Nutrition Guidelines on 'MyPlate' 3Health News:ASCO: Emerging trends in radiation therapy for women over 70 with early stage breast cancer 2Health News:UofL researchers uncover mechanism in saliva production 2Health News:Obesity Greater Risk for Fatty Liver Than Alcohol, Study Finds 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: